Responding to the news, Stephen Whitehead, Chief Executive of the ABPI, said:
“I am delighted that the pharmaceutical industry is continuing to invest significant resources in the UK. Our industry is already of huge importance to the UK economy, generating a trade surplus of £7bn every year and employing 67,000 people right across the country. This further commitment from GlaxoSmithKline will generate more jobs here and reinforce our image as a great place for companies to do business.
“The ongoing support from government has been crucial for our industry and specific measures like the patent box have been instrumental in attracting new investment. Now we must build on this and ensure the long term success of our industry by creating a strong commercial environment where pricing rewards innovation and the uptake of new innovative medicines is ensured.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Notes to Editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.